Chemotherapy-induced thrombocytopenia (CIT) causes cancer treatment to be postponed or reduced. There is currently no approved treatment. The treatment of CIT with romiplostim was studied in this prospective experiment. Romiplostim is successful in correcting CIT, and maintenance permits most patients to resume chemotherapy without recurrence of CIT.
Thrombocytopenia is a condition in which a person's blood platelet count is low. Platelets (thrombocytes) are colourless blood cells that aid in the clotting of blood. Platelets clump and form plugs in blood vessel damage to halt bleeding. Thrombocytopenia is a common complication in cancer patients. Thrombopoietin receptor agonists, thrombopoietic medicines, and other medications can be used to treat chemotherapy-induced thrombocytopenia. These medications can be used orally or intravenously.The rising cancer prevalence is predicted to increase the number of chemotherapy operations, resulting in Chemotherapy-induced Thrombocytopenia Therapeutics.
Read More@ https://bit.ly/2Z6f7Rc
